{"id":509905,"date":"2021-07-06T16:08:16","date_gmt":"2021-07-06T20:08:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/"},"modified":"2021-07-06T16:08:16","modified_gmt":"2021-07-06T20:08:16","slug":"nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/","title":{"rendered":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BELTSVILLE, Md., July  06, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pLoBmdrd2jFqGZzyE9CzbLCpZpJehxxQ6XoNVp4lM_ZsbYukTvXItKM3Qd9R8sC5eYTODsq6kPAK0LeZpR4p9w==\" rel=\"nofollow noopener\" target=\"_blank\">NextCure, Inc.<\/a> (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1\/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.<\/p>\n<p>\u201cWe are pleased to have initiated the clinical trial of our third product candidate,\u201d said Michael Richman, NextCure\u2019s president and chief executive officer. \u201cThis represents an important expansion of our pipeline of novel immunomedicines designed to treat patients who are not adequately addressed by currently available therapies. We look forward to reporting initial data from this trial in mid-2022.\u201d<\/p>\n<p>\u201cNC762 is an innovative immunomedicine that directly inhibits tumor growth by a unique, T cell independent mechanism,\u201d said Han Myint, M.D., NextCure\u2019s chief medical officer. \u201cAs B7-H4 is widely expressed on multiple tumor types, including non-small cell lung cancer, ovarian cancer and breast cancer, we believe NC762 has the potential to provide benefit in multiple cancer indications.\u201d<\/p>\n<p>The Phase 1 dose-escalation portion of this open-label trial is designed to evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and to determine its pharmacologically active and\/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, NC762 will be evaluated in select tumor types. A B7-H4 Immunohistochemistry (IHC) assay has been successfully developed and will be used for patient selection in Phase 2.<\/p>\n<p>\n        <strong>About NextCure, Inc.<\/strong><br \/>\n        <br \/>NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO\u2122 platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f7es0OSb9dbq5_f5b9OhLbn0YPu2W9Sx03DILLwmBO8uHwJ2_1P7xiT9XNKrdGIjFtjl-iXCiNHz_iwCU8MZGg==\" rel=\"nofollow noopener\" target=\"_blank\">www.nextcure.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure\u2019s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as \u201cmay,\u201d \u201cwill,\u201d \u201cpotential,\u201d \u201cexpects,\u201d \u201cbelieves,\u201d \u201cintends,\u201d \u201chope,\u201d \u201ctowards,\u201d \u201cforward,\u201d \u201clater\u201d and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the development plans for NC762 and expected upcoming milestones, the potential benefits of NC762, and NextCure\u2019s plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure\u2019s business, including NextCure\u2019s clinical trials, third parties on which NextCure relies and NextCure\u2019s operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure\u2019s limited operating history and no products approved for commercial sale; NextCure\u2019s history of significant losses; NextCure\u2019s need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure\u2019s FIND-IO platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure\u2019s actual results are described in NextCure\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including in Item 1A of NextCure\u2019s most recent Form 10-K and elsewhere in the Company\u2019s filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4913e17b-f078-49b1-832b-310c10ecdf6c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Inquiries\r\nTimothy Mayer, Ph.D.\r\nNextCure, Inc.\r\nChief Operating Officer\r\n(240) 762-6486\r\nIR@nextcure.com\r\n\r\nMedia Inquiries\r\nEmily Wong\r\nMacDougall\r\n(781) 235-3060\r\nNextCure@macbiocom.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1\/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody. \u201cWe are pleased to have initiated the clinical trial of our third product candidate,\u201d said Michael Richman, NextCure\u2019s president and chief executive officer. \u201cThis represents an important expansion of our pipeline of novel immunomedicines designed to treat patients who are not adequately addressed by currently available therapies. We look forward to reporting initial data from this trial in mid-2022.\u201d \u201cNC762 is an innovative immunomedicine that directly inhibits tumor growth by a unique, T cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-509905","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1\/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody. \u201cWe are pleased to have initiated the clinical trial of our third product candidate,\u201d said Michael Richman, NextCure\u2019s president and chief executive officer. \u201cThis represents an important expansion of our pipeline of novel immunomedicines designed to treat patients who are not adequately addressed by currently available therapies. We look forward to reporting initial data from this trial in mid-2022.\u201d \u201cNC762 is an innovative immunomedicine that directly inhibits tumor growth by a unique, T cell &hellip; Continue reading &quot;NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-06T20:08:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NextCure Initiates Phase 1\\\/2 Clinical Trial of NC762 for Solid Tumors\",\"datePublished\":\"2021-07-06T20:08:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/\"},\"wordCount\":680,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/\",\"name\":\"NextCure Initiates Phase 1\\\/2 Clinical Trial of NC762 for Solid Tumors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=\",\"datePublished\":\"2021-07-06T20:08:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NextCure Initiates Phase 1\\\/2 Clinical Trial of NC762 for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors - Market Newsdesk","og_description":"BELTSVILLE, Md., July 06, 2021 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1\/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody. \u201cWe are pleased to have initiated the clinical trial of our third product candidate,\u201d said Michael Richman, NextCure\u2019s president and chief executive officer. \u201cThis represents an important expansion of our pipeline of novel immunomedicines designed to treat patients who are not adequately addressed by currently available therapies. We look forward to reporting initial data from this trial in mid-2022.\u201d \u201cNC762 is an innovative immunomedicine that directly inhibits tumor growth by a unique, T cell &hellip; Continue reading \"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-06T20:08:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors","datePublished":"2021-07-06T20:08:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/"},"wordCount":680,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/","name":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=","datePublished":"2021-07-06T20:08:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NTg5NyM0Mjg0NTg3IzIxMjU4MzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-initiates-phase-1-2-clinical-trial-of-nc762-for-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=509905"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509905\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=509905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=509905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=509905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}